Antiretroviral therapy

Antiretroviral therapy is the principal treatment-based response to HIV-associated kidney disease in the evidence presented here. Its importance extends beyond suppression of HIV: observational experience suggests that it can alter the course of HIV-associated nephropathy and may improve the otherwise poor renal and patient survival seen in HIV/HCV coinfection, while also exposing the limits of current evidence about HCV-specific renal injury.

Role in HIV-Associated Nephropathy

Antiretroviral therapy substantially improved the grim prognosis initially reported for HIV-associated nephropathy. Although no prospective controlled trials had been completed, several cohort studies strongly suggested that treatment slows the progression of renal impairment and might even prevent HIV-associated nephropathy from developing. The therapeutic effect therefore appears both protective and disease-modifying: it is used after renal involvement is recognized, but the available observations also support earlier control of HIV as a possible means of reducing renal complications.

The evidence places antiretroviral therapy alongside blockade of the renin–angiotensin system rather than treating it as an isolated renal maneuver. Renin–angiotensin blockade decreases proteinuria and slows the progression of renal failure, whereas antiretroviral therapy addresses the viral process implicated in HIV-associated nephropathy. Together, these measures frame management around both the underlying infection and its glomerular consequences.

HIV/HCV Coinfection and Glomerular Disease

Patients with HIV/HCV coinfection can develop several immune-complex glomerular diseases in addition to the classical collapsing form of HIV-associated nephropathy. Reported lesions include membranoproliferative glomerulonephritis, IgA nephropathy, non-collapsing focal segmental glomerulosclerosis, membranous nephropathy, and lupus-like glomerulonephritis. The clinical course is aggressive in a majority of reported patients, and renal biopsy is often required because clinical findings alone cannot reliably establish the precise lesion or its prognosis.

The specific role of HCV is difficult to determine in these cases. Many coinfected patients with biopsy-proven membranoproliferative glomerulonephritis also had circulating cryoglobulins, allowing their disease to be interpreted as HCV-related cryoglobulinemic membranoproliferative glomerulonephritis, as in patients without HIV. Yet systemic manifestations of cryoglobulinemia appeared uncommon, and HCV may also contribute to immune-complex diseases other than membranoproliferative glomerulonephritis. Antiretroviral therapy is consequently recommended for patients with HIV and glomerular disease whether or not HCV coinfection is present.

Prognosis and Limits of the Evidence

Before widespread antiretroviral treatment, glomerular disease in HIV/HCV-coinfected patients was associated with very poor patient and renal survival. In the only cited series in which most patients received antiretroviral therapy, the prognosis appeared significantly better than in earlier reports. The improvement is consistent with the favorable experience in HIV-associated nephropathy, but it does not establish how much benefit comes from HIV control, how much from changes in immune activation, or how much may be influenced by differences in patient selection and supportive care.

The evidence remains notably incomplete. There is little direct information about the results of HCV-directed treatment in coinfected patients whose principal problem is glomerular disease rather than liver disease. The need for such studies is especially urgent in biopsy-proven membranoproliferative glomerulonephritis with circulating cryoglobulins and severe renal presentations such as nephrotic syndrome or deteriorating renal function.

Relationship to HCV-Directed and Immunosuppressive Treatment

While awaiting stronger evidence, HCV-directed therapy with interferon and ribavirin was considered logical for selected coinfected patients with biopsy-proven membranoproliferative glomerulonephritis, circulating cryoglobulins, and severe renal disease. This recommendation addresses the possibility that HCV is driving the immune-complex process, but it does not replace antiretroviral therapy, which should be prescribed for the HIV infection itself.

Corticosteroids and other immunosuppressive agents, particularly rituximab, have been proposed for HCV-related cryoglobulinemic membranoproliferative glomerulonephritis. Their use in HIV-infected patients remains supported by very limited information, and severe adverse effects may be common when immunosuppression is added to HIV/HCV coinfection. Antiretroviral therapy therefore occupies the comparatively secure therapeutic ground in this discussion: it has cohort-based support for improving renal outcomes, whereas HCV-specific antiviral therapy and immunosuppression require more narrowly defined indications and substantially stronger safety data.